Pipeline
Our initial programs with evorpacept (ALX148) are focused on targeting CD47 across various oncology indications. Many forms of cancer use CD47 expression as a means of evading immune response. We are targeting the hematologic malignancies and solid tumor indications where we believe we have the greatest potential to address large unmet medical needs.
HNSCC
Head and Neck Squamous Cell Carcinoma
HNSCC
Head and Neck Squamous Cell Carcinoma
GC
Gastric/Gastroesophageal Junction Cancer
GC
Gastric/Gastroesophageal Junction Cancer
Urothelial Cancer
Breast Cancer
Breast Cancer
MDS
Myelodysplastic Syndromes
AML
Acute Myeloid Leukemia
NHL
Non-Hodgkin's Lymphoma
002*
Advanced Cancer
*SIRPα Toll-like receptor agonist antibody conjugate (TRAAC)
Clinical Trials
ALX Oncology Sponsored Trials
- A Study of ALX148 in Patients with Advanced Solid Tumors and Lymphoma
(ASPEN-01) - A Study of ALX148 with Azacitidine for Higher Risk Myelodysplastic Syndrome
(ASPEN-02) - ALX148 in Combination with Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma
(ASPEN-03) - ALX148 in Combination with Pembrolizumab and Chemotherapy in Patients with Advanced Head and Neck Squamous Cell Carcinoma
(ASPEN-04) - A Study of Evorpacept (ALX148) with Venetoclax and Azacitidine for Acute Myeloid Leukemia
(ASPEN-05) - A Study of Evorpacept (ALX148) in Patients with Advanced HER2+ Gastric Cancer
(ASPEN-06) - A Study of Evorpacept (ALX148) with Enfortumab Vedotin for Subjects with Urothelial Carcinoma
(ASPEN-07)
Collaboration Partner Sponsored Trials
Investigator Sponsored Trials
Expanded Access Policy
ALX Oncology is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system. The goal of our current clinical study program is to enroll patients and obtain clinical data on evorpacept that is required by the US Food and Drug Administration (FDA) and other regulatory authorities for review and approval of marketing applications for this investigational agent.
We believe that focusing on clinical studies is the most appropriate way to achieve this goal; therefore, we do not currently offer access to evorpacept outside of clinical studies and, at this time, we have no Expanded Access Program (sometimes referred to as “compassionate use” or “pre-approval access”).
If you have additional questions regarding this policy, please speak with your health care provider or contact: info@alxoncology.com